About
Laboratoire de recherche du vieillissement. Drug discovery, biomarkers, cellular reprogramming, aging biology.
Headquarters
San Francisco, California, USA
Founded
2013
Type
Laboratory
Ecosystems
1
Legal identity
- Legal name
- Calico Life Sciences LLC
- Status
- Active
- Verified on
- 2026-08-30
- Review due
- 2026-11-30
Mission
“Harness advanced technologies to increase human healthspan.”
Focus areas
Aging biologyDrug discoverySenolyticsCellular reprogrammingBiomarkers
Ecosystem participation
Strategic roadmap
2025 Q4
● ActiveABBV-CLS-628 enters Phase 2 for ADPKD
Calico reported on 2 October 2025 that its anti-PAPP-A monoclonal antibody had received FDA Fast Track designation and was enrolling an ongoing Phase 2 trial for autosomal dominant polycystic kidney disease. It is not described as a senolytic.
Longevity & Anti-Aging
2026 Q4
◯ PlannedCombination therapy trials initiate
Multiple senolytic agents + reprogramming regimen.
Longevity & Anti-Aging
2028 Q2
◯ PlannedAge reversal demonstrated 5+ years
Biomarker validation. Aging reversal in humans.
Longevity & Anti-Aging